Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal

被引:5
|
作者
Ando, Yukio [1 ]
Waddington-Cruz, Marcia [2 ]
Sekijima, Yoshiki [3 ]
Koike, Haruki [4 ,5 ]
Ueda, Mitsuharu [6 ]
Konishi, Hiroaki [7 ]
Ishii, Tomonori [7 ]
Coelho, Teresa [8 ]
机构
[1] Nagasaki Int Univ, Fac Pharmaceut Sci, Dept Amyloidosis Res, 2825-7 Huis Ten Bosch Sasebo, Sasebo, Nagasaki 8593298, Japan
[2] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Ctr Estudos Paramiloidose Antonio Rodrigues Mello, Rio De Janeiro, RJ, Brazil
[3] Shinshu Univ, Sch Med, Dept Med Neurol & Rheumatol, Matsumoto, Japan
[4] Nagoya Univ, Dept Neurol, Grad Sch Med, Nagoya, Japan
[5] Saga Univ, Fac Med, Dept Internal Med, Div Neurol, Saga, Japan
[6] Kumamoto Univ, Grad Sch Med Sci, Dept Neurol, Kumamoto, Japan
[7] Pfizer Japan Inc, Tokyo, Japan
[8] Ctr Hosp Univ Porto, Hosp Santo Antonio, Andrades Ctr Familial Amyloidosis, Porto, Portugal
关键词
Asymptomatic; ATTR amyloidosis; Biopsy; Cardiomyopathy; Gene mutation carrier; Genetic counseling; Neuropathy; Noninvasive testing; Practical guidance; Predictive genetic testing; CARPAL-TUNNEL-SYNDROME; DIAGNOSTIC-ACCURACY; POLYNEUROPATHY; SYMPTOM; ONSET; PROGRESSION; PREVALENCE; TAFAMIDIS; CONSENSUS; FOCUS;
D O I
10.1186/s13023-023-02910-3
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Hereditary transthyretin (ATTRv) amyloidosis is a rare and autosomal dominant disorder associated with mutations in the transthyretin gene. Patients present with diverse symptoms related to sensory, motor, and autonomic neuropathy, as well as gastrointestinal, ocular, cardiac, renal and orthopedic symptoms, resulting from the deposition of transthyretin amyloid fibrils in multiple organs. The progressive nature of ATTRv amyloidosis necessitates pre- and post-onset monitoring of the disease. This review article is primarily based on a collation of discussions from a medical advisory board meeting in August 2021. In this article, we summarize the best practices in amyloidosis centers in three major endemic countries for ATTRv amyloidosis (Japan, Brazil, and Portugal), where most patients carry the Val30Met mutation in the transthyretin gene and the patients' genetic background was proven to be the same. The discussions highlighted the similarities and differences in the management of asymptomatic gene mutation carriers among the three countries in terms of the use of noninvasive tests and tissue biopsies and timing of starting the investigations. In addition, this article discusses a set of practical tests and examinations for monitoring disease progression applicable to neurologists working in diverse medical settings and generalizable in non-endemic countries and areas. This set of assessments consists of periodic (every 6 to 12 months) evaluations of patients' nutritional status and autonomic, renal, cardiac, ophthalmologic, and neurological functions. Physical examinations and patient-reported outcome assessments should be also scheduled every 6 to 12 months. Programs for monitoring gene mutation carriers and robust referral networks can aid in appropriate patient management in pre- to post-onset stages. For pre- and post-symptom onset testing for ATTRv amyloidosis, various noninvasive techniques are available; however, their applicability differs depending on the medical setting in each country and region, and the optimal option should be selected in view of the clinical settings, medical environment, and available healthcare resources in each region.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Role of blood biomarkers in hereditary transthyretin amyloidosis: a realworld experience from a single center
    Russo, Massimo
    De Luca, Marcella
    Gentile, Luca
    Iabichella, Giacomo
    Darma, Federica
    Aguennouz, M'hammed
    Mazzeo, Anna
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 : S207 - S207
  • [32] Screening and profile of cardiac involvement in patients with hereditary transthyretin amyloidosis from a reference center in Brazil
    de Souza, Fabio
    da Silva, Lucas Fonseca
    Fernandes da Silva, Yuri Vianna
    Foureaux, Matheus Medeiros
    Correa Filho, Wilson Braz
    Vedoveli Francisco, Claudia Elena
    Tassi, Eduardo Marinho
    Franz, Cibele
    Bittar-Braune, Caroline
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 : S33 - S33
  • [33] Initial real-world experience of clazosentan for subarachnoid hemorrhage in Japan
    Maeda, Takuma
    Okawara, Mai
    Osakabe, Manabu
    Yamaguchi, Hiroyuki
    Maeda, Takahiro
    Kurita, Hiroki
    WORLD NEUROSURGERY-X, 2024, 21
  • [34] Management of gastrointestinal complications in hereditary transthyretin amyloidosis: a single-center experience over 40 years
    Wixner, Jonas
    Suhr, Ole B.
    Anan, Intissar
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 12 (01) : 73 - 81
  • [35] Management of Thrombocytopenia in Patients With Hereditary Transthyretin Amyloidosis Treated With Inotersen: Clinical Trial and Postmarketing Surveillance Experience
    Gertz, M.
    Khella, S.
    Wang, A.
    Coelho, T.
    Waddington Cruz, M.
    Polydefkis, M. J.
    Plante-Bordeneuve, V.
    Berk, J. L.
    Barroso, F.
    Brannagan, T. H., III
    Merlini, G.
    Obici, L.
    Conceicao, I.
    Jung, S. W.
    Hughes, S. G.
    Aquino, P.
    O'dea, L. S. L.
    Narayana, A.
    Dasgupta, N.
    Benson, M. D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 404 - 405
  • [36] MULTIDISCIPLINARY APPROACH TO THE DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH HEREDITARY AMYLOID TRANSTHYRETIN AMYLOIDOSIS: A SINGLE-CENTER EXPERIENCE
    Peltier, Amanda
    Rubinstein, Samuel
    Punnoose, Lynn
    Wigger, Mark A.
    MUSCLE & NERVE, 2020, 62 : S60 - S60
  • [37] Coexisting Calcific Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Real-World Evaluation of Clinical Characteristics and Outcomes
    Masri, Ahmad
    Chen, Yong
    Colavecchia, A. Carmine
    Benjumea, Darrin
    Crowley, Aaron
    Jhingran, Priti
    Kent, Matthew
    Wogen, Jenifer
    Pankratova, Cindi
    Alvir, Jose Maria Jimenez
    Bhambri, Rahul
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2025, 14 (02):
  • [38] Characteristics and treatment of contemporary real-world patients with cardiac transthyretin amyloidosis: a retrospective, multicenter, observational study
    Pfister, R. Roman
    Ney, S.
    Kindermann, I.
    Knebel, F.
    Luedike, P.
    Morbach, C.
    Polzin, A.
    Unsoeld, B.
    Yilmaz, A.
    Nies, R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 153 - 153
  • [39] Real-world experience with caplacizumab in the management of acute TTP
    Dutt, Tina
    Shaw, Rebecca J.
    Stubbs, Matthew
    Yong, Jun
    Bailiff, Benjamin
    Cranfield, Tanya
    Crowley, Maeve P.
    Desborough, Michael
    Eyre, Toby A.
    Gooding, Richard
    Grainger, John
    Hanley, John
    Haughton, Joanna
    Hermans, Joannes
    Hill, Quentin
    Humphrey, Louise
    Lowe, Gillian
    Lyall, Hamish
    Mohsin, Muhammad
    Nicolson, Phillip L. R.
    Priddee, Nicole
    Rampotas, Alexandros
    Rayment, Rachel
    Rhodes, Susan
    Taylor, Alice
    Thomas, William
    Tomkins, Oliver
    Van Veen, Joost J.
    Lane, Steven
    Toh, Cheng-Hock
    Scully, Marie
    BLOOD, 2021, 137 (13) : 1731 - 1740
  • [40] REAL-WORLD EXPERIENCE WITH IDARUCIZUMAB FOR THE MANAGEMENT OF DABIGATRAN REVERSAL
    Raco, Veronica
    Ahuja, Tania
    Green, David
    CRITICAL CARE MEDICINE, 2018, 46 (01) : 47 - 47